ST Nanxin (688189.SH): Phase III clinical trial of Peramivir Inhalation Solution met the pre-specified primary endpoint.

Gelonghui, June 11 — ST Nanxin (688189.SH) announced that its independently developed Class 2.2 modified new drug, peramivir inhalation solution, has met the pre-specified primary endpoint in a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial titled “A Study Evaluating the Efficacy and Safety of Peramivir Inhalation Solution in Adult Patients with Uncomplicated Influenza” (Registration No.: CTR20244827). The company will subsequently submit a Pre-NDA meeting request to the Center for Drug Evaluation (CDE) of the National Medical Products Administration and actively advance the marketing application for peramivir inhalation solution.

Gelonghui Finance18:00

Express News | Stock Market Lightning Rod – June 10

BreakingsJun 10 08:37

Nanxin Pharmaceutical was fined for financial fraud involving an artificial inflation of total profits by RMB 119.522 million and will be designated with a special treatment (ST) status.

① Nanxin Pharmaceutical overstated its 2023 revenue by RMB 64.6828 million, accounting for 8.69% of its reported revenue for the period, and overstated its profit before tax by RMB 11.9522 million, equivalent to 157.11% of its reported profit before tax for the period. ② However, despite holding paramivir sodium chloride injection, Nanxin Pharmaceutical's financial performance in recent years has been disappointing, with continuously declining revenue and persistent losses.

cls.cnJun 10 08:00

Morning Brief by Xiao K | Guangdong: Encourages development of integrated solar-power-storage-charging infrastructure; Anthropic releases new Mythos series models

① Samsung and SK Hynix are reportedly set to announce investment plans in Korea; ② Deutsche Bank: The semiconductor inventory rebound reflects front-loading rather than weakening demand; ③ Biwin Storage: Signed a $1.861 billion enterprise-grade NAND flash memory chip procurement contract.

cls.cnJun 10 07:56

Several A-share companies fined for fund misappropriation, revenue inflation, internal control violations, and short-swing trading | Announcement Highlights

① Several A-share companies received regulatory penalties within a single day; ② violations involved fund misappropriation, inflated revenue, internal control breaches, and short-swing trading.

cls.cnJun 10 00:20

Sci-Tech Innovation Board Evening Report | Biwin Storage Signs $1.861 Billion Procurement Contract; E-Show Silicon Plans to Participate in Acquisition of 60% Equity Stake in Jinglong Semiconductor

① Gridsum DeepView: Does not directly engage in physical AI-related products or business; ② Nanxin Pharmaceutical: Effective June 11, the stock ticker will be changed to “ST Nanxin”; ③ Semiway Microelectronics: During the period of abnormal stock price fluctuations, controlling shareholders Zhao Jianhua and Ge Weiguo engaged in share sales; ④ Novogene: The basis for its inclusion on the U.S. Department of Defense’s Section 1260H list is entirely inconsistent with the facts.

cls.cnJun 9 21:05